Colonial River Wealth Management LLC Makes New $554,000 Investment in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Colonial River Wealth Management LLC purchased a new position in IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report) in the fourth quarter, Holdings Channel.com reports. The firm purchased 999 shares of the company’s stock, valued at approximately $554,000.

A number of other institutional investors have also bought and sold shares of IDXX. Moneta Group Investment Advisors LLC boosted its holdings in shares of IDEXX Laboratories by 121,647.2% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 7,447,279 shares of the company’s stock valued at $3,038,192,000 after purchasing an additional 7,441,162 shares during the last quarter. State Street Corp boosted its holdings in shares of IDEXX Laboratories by 2.6% during the 2nd quarter. State Street Corp now owns 3,771,574 shares of the company’s stock valued at $1,894,198,000 after purchasing an additional 97,303 shares during the last quarter. Alliancebernstein L.P. boosted its holdings in shares of IDEXX Laboratories by 6.4% during the 2nd quarter. Alliancebernstein L.P. now owns 3,592,832 shares of the company’s stock valued at $1,804,428,000 after purchasing an additional 214,529 shares during the last quarter. Geode Capital Management LLC boosted its holdings in shares of IDEXX Laboratories by 1.4% during the 1st quarter. Geode Capital Management LLC now owns 1,946,339 shares of the company’s stock valued at $971,569,000 after purchasing an additional 26,197 shares during the last quarter. Finally, Blair William & Co. IL boosted its holdings in shares of IDEXX Laboratories by 0.7% during the 3rd quarter. Blair William & Co. IL now owns 1,199,945 shares of the company’s stock valued at $524,700,000 after purchasing an additional 7,812 shares during the last quarter. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. The Goldman Sachs Group increased their price objective on shares of IDEXX Laboratories from $500.00 to $650.00 and gave the company a “buy” rating in a report on Wednesday, January 17th. JPMorgan Chase & Co. increased their price target on shares of IDEXX Laboratories from $600.00 to $630.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. StockNews.com raised shares of IDEXX Laboratories from a “hold” rating to a “buy” rating in a report on Wednesday, December 20th. Barclays increased their price target on shares of IDEXX Laboratories from $605.00 to $655.00 and gave the company an “overweight” rating in a report on Tuesday, February 6th. Finally, BNP Paribas started coverage on shares of IDEXX Laboratories in a report on Thursday, December 7th. They issued an “outperform” rating and a $602.00 price target for the company. Three analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to data from MarketBeat.com, IDEXX Laboratories presently has an average rating of “Moderate Buy” and a consensus price target of $591.50.

Read Our Latest Stock Report on IDEXX Laboratories

IDEXX Laboratories Trading Down 2.0 %

NASDAQ IDXX traded down $10.74 during trading on Tuesday, hitting $521.67. The stock had a trading volume of 382,312 shares, compared to its average volume of 425,570. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.17 and a current ratio of 1.57. The stock has a market capitalization of $43.32 billion, a price-to-earnings ratio of 51.80, a P/E/G ratio of 2.96 and a beta of 1.26. IDEXX Laboratories, Inc. has a one year low of $372.50 and a one year high of $583.39. The stock has a 50 day simple moving average of $548.88 and a 200 day simple moving average of $503.75.

IDEXX Laboratories (NASDAQ:IDXXGet Free Report) last announced its quarterly earnings data on Monday, February 5th. The company reported $2.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.12 by $0.20. The business had revenue of $901.60 million during the quarter, compared to the consensus estimate of $891.88 million. IDEXX Laboratories had a net margin of 23.08% and a return on equity of 71.66%. The firm’s quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter last year, the firm earned $2.05 earnings per share. Sell-side analysts predict that IDEXX Laboratories, Inc. will post 11.15 earnings per share for the current year.

Insider Transactions at IDEXX Laboratories

In other news, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the transaction, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at $16,939,557.18. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CFO Brian P. Mckeon sold 23,326 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The shares were sold at an average price of $570.01, for a total transaction of $13,296,053.26. Following the transaction, the chief financial officer now directly owns 29,718 shares of the company’s stock, valued at $16,939,557.18. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CEO Jonathan Jay Mazelsky sold 12,000 shares of the firm’s stock in a transaction that occurred on Wednesday, February 7th. The stock was sold at an average price of $572.61, for a total transaction of $6,871,320.00. Following the transaction, the chief executive officer now directly owns 79,247 shares in the company, valued at $45,377,624.67. The disclosure for this sale can be found here. Over the last three months, insiders have sold 43,524 shares of company stock valued at $24,871,960. 2.11% of the stock is currently owned by company insiders.

IDEXX Laboratories Company Profile

(Free Report)

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Recommended Stories

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXXFree Report).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.